agm today, page-9

Yes the ops move gives less risk to the sp, and makes the company more attractive as a T/O also makes it more attractive to Board purchasing stock prior to an announcement!
Trial results have had a high degree of variability thats very true and have bee done on to small a sample IMHO but the nano market cap is small for a company at this stage of devpt
They should not worry about FDA approval instead go the European route dueto the plant based product liked by German pharmacies
I would be hesitant about holding too much in this as it is extremely speculative so many wonder cancer treatment companies out there!